Clindamycin And Benzoyl Peroxide NDC 72162-2074

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2074Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2074Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2074-2	72162207402	1 KIT in 1 CARTON (72162-2074-2) * .6 g in 1 VIAL * 39.4 g in 1 JARMarketed from Aug 15, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clindamycin And Benzoyl Peroxide
Generic name (nonproprietary): clindamycin and benzoyl peroxide
Dosage form: Kit
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202440
Marketing start: Sep 22, 2015
Listing expires: Dec 31, 2026
Identifiers: Product ID 72162-2074_0eac69b9-110e-4e7a-bfbd-7fd40a40f5eaSPL ID 0eac69b9-110e-4e7a-bfbd-7fd40a40f5eaSPL set ID 30d311b4-9058-4ebf-898e-17ba66294500RxCUI 308694, 358917

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N472162207402 followed by a unit qualifier and the quantity

Package 72162-2074-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 15, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Clindamycin and benzoyl peroxide topical gel, 1%/5% is indicated for the topical treatment of acne vulgaris.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)